company background image
MMQ logo

Mind Medicine (MindMed) DB:MMQ Stock Report

Last Price

€7.25

Market Cap

€576.6m

7D

11.5%

1Y

86.3%

Updated

08 Jan, 2025

Data

Company Financials +

Mind Medicine (MindMed) Inc.

DB:MMQ Stock Report

Market Cap: €576.6m

MMQ Stock Overview

A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. More details

MMQ fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 97.6% below our estimate of its fair value

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Mind Medicine (MindMed) Inc. Competitors

PharmaSGP Holding

XTRA:PSG

€314.1m

Dermapharm Holding

XTRA:DMP

€2.2b

Pierrel

DB:2FJ0

€92.8m

MPH Health Care

DB:93M1

€101.9m

Price History & Performance

Summary of share price highs, lows and changes for Mind Medicine (MindMed)
Historical stock prices
Current Share PriceUS$7.25
52 Week HighUS$12.03
52 Week LowUS$3.21
Beta2.41
1 Month Change1.05%
3 Month Change51.86%
1 Year Change86.28%
3 Year Change-55.16%
5 Year Changen/a
Change since IPO35.77%

Recent News & Updates

Recent updates

Shareholder Returns

MMQDE PharmaceuticalsDE Market
7D11.5%2.2%1.7%
1Y86.3%-15.0%9.4%

Return vs Industry: MMQ exceeded the German Pharmaceuticals industry which returned -14.7% over the past year.

Return vs Market: MMQ exceeded the German Market which returned 9.6% over the past year.

Price Volatility

Is MMQ's price volatile compared to industry and market?
MMQ volatility
MMQ Average Weekly Movement14.5%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: MMQ's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: MMQ's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a57Rob Barrowwww.mindmed.co

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Mind Medicine (MindMed) Inc. Fundamentals Summary

How do Mind Medicine (MindMed)'s earnings and revenue compare to its market cap?
MMQ fundamental statistics
Market cap€576.64m
Earnings (TTM)-€94.83m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.1x

P/E Ratio

Is MMQ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MMQ income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$97.80m
Earnings-US$97.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.33
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio9.3%

How did MMQ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 09:27
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mind Medicine (MindMed) Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Sumant Satchidanand KulkarniCanaccord Genuity
Tania Armstrong-WhitworthCanaccord Genuity